Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 2132, Suchdauer: 1.29s

12 3 4 5 6 7 8 9 10 11 weiter »

1
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study

von Maria Argente-Pla ; Miguel Antonio Sampedro-Nuñez ; Rocio Garcia-Carbonero ; et al.

Frontiers in Nutrition, Vol 13 (2026)

Schlagworte: gastroenteropancreatic; malnutrition; neuroendocrine neoplasms; predictive tools; prognostic factors; sarcopenia; Nutrition. Foods and food supply; TX341-641
- View full text via DOI
Merkliste

2
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

von Marcia S. Brose ; Bhumsuk Keam ; Jolanta Krajewska ; et al.

Frontiers in Oncology, Vol 16 (2026)

Schlagworte: BRAF; BRAFV600E; cabozantinib; COSMIC-311; PFS; RAIR-DTC; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

3
Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

von Jesús Yaringaño ; Jorge Hernando ; Alejandro García-Álvarez ; et al.

Frontiers in Oncology, Vol 16 (2026)

Schlagworte: ALK (anaplastic lymphoma kinase); lorlatinib; sequential treatment ALK-TKI; targeted therapy; thyroid cacinoma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

4
Besicovitch's example in higher dimensions: a purely unrectifiable set with large lower density

von Capdevila, Jaume

Schlagworte: Classical Analysis and ODEs
- View full text via Arxiv
Merkliste

5
Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus

von Aleš Ryška ; Jaume Capdevila ; Matthias S Dettmer ; et al.

European Thyroid Journal, Vol 14, Iss 4 (2025)

Schlagworte: biomarkers; consensus; molecular testing; thyroid cancer; multidisciplinary; Diseases of the endocrine glands. Clinical endocrinology; RC648-665
- View full text via DOI
Merkliste

6
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

von Maria Carmen Riesco-Martinez ; Jaume Capdevila ; Vicente Alonso ; et al.

Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)

Schlagworte: Science
- View full text via DOI
Merkliste

7
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

von Maria Balaguer-Montero ; Adrià Marcos Morales ; Marta Ligero ; et al.

Cell Reports Medicine, Vol 6, Iss 4, Pp 102032- (2025)

Schlagworte: liver tumors; detection; delineation; deep learning; imaging; Medicine (General); R5-920
- View full text via DOI
Merkliste

8
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

von Simron Singh ; Diego Ferone ; Jaume Capdevila ; et al.

Trials, Vol 25, Iss 1, Pp 1-13 (2024)

Schlagworte: CAM2029; GEP-NET; High bioavailability; High plasma exposure; Octreotide; Randomised active-controlled; Medicine (General); R5-920
- View full text via DOI
Merkliste

9
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

von Jaume Capdevila ; Desiree’ Deandreis ; Cosimo Durante ; et al.

European Thyroid Journal, Vol 12, Iss 5, Pp 1-11 (2023)

Schlagworte: differentiated thyroid cancer; lenvatinib; radioiodine refractory; toxicity; management; Diseases of the endocrine glands. Clinical endocrinology; RC648-665
- View full text via DOI
Merkliste

10
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

von Sophie Leboulleux ; Ellen Kapiteijn ; Saskia Litière ; et al.

Frontiers in Endocrinology, Vol 15 (2024)

Schlagworte: nintedanib; RAIR DTC; MTC; phase II trial; triple-angiokinase inhibitor; Diseases of the endocrine glands. Clinical endocrinology; RC648-665
- View full text via DOI
Merkliste

11
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

von Salvatore Grisanti ; Vivek Subbiah ; Eric Baudin ; et al.

Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

12
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

von Estefania Cuesta-Borràs ; Cándida Salvans ; Oriol Arqués ; et al.

Cell Reports, Vol 42, Iss 8, Pp 112927- (2023)

Schlagworte: CP: Cancer; Biology (General); QH301-705.5
- View full text via DOI
Merkliste

13
Impact of the COVID-19 pandemic in the early-onset colorectal cancer

von Iosune Baraibar ; Ariadna García ; Francesc Salvà ; et al.

Translational Oncology, Vol 32, Iss , Pp 101668- (2023)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

14
Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe

von Rossella Elisei ; Enrique Grande ; Michael C. Kreissl ; et al.

Frontiers in Oncology, Vol 13 (2023)

Schlagworte: thyroid cancer; tyrosine kinase inhibitor; medullary thyroid cancer; papillary thyroid cancer; receptor-tyrosine kinase; RET; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

15
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

von Simron Singh ; Diego Ferone ; Jaume Capdevila ; et al.

Trials, Vol 25, Iss 1, Pp 1-1 (2024)

Schlagworte: Medicine (General); R5-920
- View full text via DOI
Merkliste

16
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

von Lucía Trilla-Fuertes ; Angelo Gámez-Pozo ; Joan Maurel ; et al.

Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)

Schlagworte: Medicine; Science
- View full text via DOI
Merkliste

17
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

von Marta Benavent ; Javier Sastre ; Ignacio García Escobar ; et al.

Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-11 (2021)

Schlagworte: Neuroendocrine tumours; Health-related quality of life; QLQ-GINET21 questionnaire; Communication; Clinical utility; Computer applications to medicine. Medical informatics; R858-859.7
- View full text via DOI
Merkliste

18
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results

von Ramón Salazar ; Jaume Capdevila ; Jose Luis Manzano ; et al.

BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)

Schlagworte: Locally-advanced rectal cancer; Bevacizumab; Neoadjuvant; Chemoradiotherapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

19
What is the status of immunotherapy in thyroid neoplasms?

von Alejandro Garcia-Alvarez ; Jorge Hernando ; Ana Carmona-Alonso ; et al.

Frontiers in Endocrinology, Vol 13 (2022)

Schlagworte: thyroid neoplasms; immunotherapy; PD-L1; tumor mutational burden; tumor microenvironment; Diseases of the endocrine glands. Clinical endocrinology; RC648-665
- View full text via DOI
Merkliste

20
Evolving landscape of targeted therapies in early phase clinical trials

von Rossi, Alice ; Braña, Irene ; Vieito, Maria ; et al.

In European Journal of Cancer 3 June 2026 240
- View full text via DOI
Merkliste

21
Primary hepatic gastrinoma as a clinical mimic: Favorable clinical outcomes

von Sanchis-Pascual, David ; de Miguel-Rodríguez, Luis ; Morillas-Amat, Pilar ; et al.

In Endocrinología, Diabetes y Nutrición (English ed.) June-July 2026 73(6)
- View full text via DOI
Merkliste

22
Genotype-phenotype correlations and putative modifier genes in SYNGAP1 Encephalopathy

von Aranda, Selena ; Ribeiro-Constante, Juliana ; Tristán-Noguero, Alba ; et al.

In Neurobiology of Disease May 2026 222
- View full text via DOI
Merkliste

23
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

von Daniel Castellano ; Andrea B. Apolo ; Camillo Porta ; et al.

Therapeutic Advances in Medical Oncology, Vol 14 (2022)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

24
Cabozantinib for the treatment of solid tumors: a systematic review

von Pablo Maroto ; Camillo Porta ; Jaume Capdevila ; et al.

Therapeutic Advances in Medical Oncology, Vol 14 (2022)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

25
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

von Oriol Mirallas ; Francesca Filippi-Arriaga ; Irene Hernandez Hernandez ; et al.

Frontiers in Endocrinology, Vol 12 (2021)

Schlagworte: capecitabine; temozolomide; aggressive pituitary tumors; Nelson’s syndrome; case report; Diseases of the endocrine glands. Clinical endocrinology; RC648-665
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag